Business context and reporting period
The supplied filing is ARCA biopharma, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2020—not a filing identified as Oruka Therapeutics, Inc. Investors should verify the issuer and filing before relying on this summary. ARCA is a clinical-stage biopharmaceutical company with no product revenue. Its lead programs are AB201, being developed as a potential COVID-19 treatment, and Gencaro for atrial fibrillation in certain heart-failure patients.
Financial performance and position
Unless otherwise noted, amounts are in millions of dollars.
| Metric | Three months ended June 30, 2020 | Six months ended June 30, 2020 | Comparable 2019 period |
|---|---|---|---|
| Revenue | None to date | None to date | None to date |
| Research and development expense | $0.372 | $0.737 | $0.440 and $1.102 |
| General and administrative expense | $0.938 | $1.913 | $1.068 and $2.187 |
| Net loss | $1.302 | $2.622 | $1.436 and $3.100 |
| Basic and diluted loss per share | $0.73 | $1.55 | $1.14 and $2.87 |
At June 30, cash and cash equivalents were $11.041, versus $8.363 at December 31, 2019. Current assets were $11.573 and current liabilities $1.328; stockholders’ equity was $10.305. The filing reports no material borrowing balance; interest expense was $0.003 for the quarter and $0.007 for the six months. The company had no marketable securities. Margins are not meaningful because it had no revenue.
For the first six months, operating cash use was $2.728, investing cash use was $0.006, and financing provided $5.412, producing a $2.678 increase in cash. Financing mainly reflected equity proceeds, net of offering costs and vendor-finance repayments.
Changes, outlook and key risks
- Compared with 2019, six-month R&D expense fell about $0.365 and G&A expense fell $0.274; net loss narrowed by $0.478. Management attributed expense reductions mainly to lower personnel and outside-service costs.
- After quarter-end, ARCA reported raising $24.1 million net from common-stock sales during July 1–31, 2020. It estimated cash at June 30 plus those proceeds would fund operations at the current cost structure and projected AB201 development costs through the end of Q4 2021. This is a management estimate, subject to assumptions; further funding is needed for clinical trials, including Gencaro.
- Management planned to submit an AB201 IND in Q3 2020 and, subject to FDA guidance and financing, begin a Phase 2 trial in Q4 2020. The filing states AB201 had not been tested in COVID-19 preclinical models or in patients with COVID-19; prior clinical experience was in other settings.
- PRECISION-AF, the planned Phase 3 Gencaro trial, was on hold due to the pandemic and prioritization of AB201. Enrollment might begin in 2021, subject to financing, pandemic conditions and patient availability. AB171 development was also contingent on capital.
- Key risks include substantial future financing needs, equity dilution, possible inability to secure funding or a strategic partner, trial and regulatory uncertainty, patient enrollment and manufacturing dependencies, and pandemic-related disruption. Management noted that the 2019 audit had identified substantial doubt about going concern; the interim statements assume continued operations.
- Potential Gencaro license payments include an $8.0 million U.S. approval milestone and up to $5.0 million for European and Japanese approvals, plus royalties under the license terms; the filing says a prior transaction reduced or eliminated certain obligations. No legal proceedings were reported. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Confirm the filing is for ARCA biopharma, Inc.; the request metadata names Oruka Therapeutics, Inc.
- Verify the July financing proceeds, share issuance and resulting dilution, and the remaining capacity under the new $54.0 million at-the-market agreement.
- Track FDA guidance, IND submission and actual trial initiation for AB201, as well as the evidence needed to support its proposed COVID-19 use.
- Confirm the funding, timing and restart prospects for PRECISION-AF and any future AB171 work.
- Assess cash burn against management’s Q4 2021 runway estimate and the financing required beyond that period.